Figure 4
Treatment outcome of MRDneg group. (A) Duration of CR (vs BM relapse) in cases with probe(s) sensitivity of 10−4 or higher; (B) DFS according to clinical risk class and (C) number of molecular markers used for MRD analysis.
Treatment outcome of MRDneg group. (A) Duration of CR (vs BM relapse) in cases with probe(s) sensitivity of 10−4 or higher; (B) DFS according to clinical risk class and (C) number of molecular markers used for MRD analysis.
